Overview / Abstract: |
Target Audience This activity is designed to meet the educational needs of Retina Specialists, Retina Fellows, Ophthalmologists (general/comprehensive), Optometrists, and allied health professionals involved in the treatment of patients with Wet Age-related Macular Degeneration. Program Overview Therapeutic options for prevention and management of diabetic eye disease have expanded, as recent trial data (PANORAMA; DRCR Protocol W) have established that therapeutic intervention can reverse disease progression (improvements in Diabetic Retinopathy Severity Scale) in diabetic patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME). This treatment of NPDR may go beyond the current treatment algorithm and provide an opportunity to prevent progression to neovascular vision-threatening complications or DME, thereby lowering burden of illness, and enhancing visual outcomes and overall quality of life for patients. Additionally, physicians are faced with new challenges associated with patient care and adherence in the era of COVID-19. Learning Objectives Upon completion of this activity, participants should be better able to: Describe the PDS mechanism of continuous delivery via passive diffusion. |
Expiration |
Jul 11, 2022 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
1.0 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Arshad Khanani, MD Nancy Holecamp, MD, FASRS Carl Regillo, MD Michael Singer, MD |
Sponsors / Supporters / Grant Providers |
Genentech, a member of the Roche Group. |
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCME., Retina Free CE CME |